Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years.
about
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis CAcute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patientsHepatitis C in clinical practice.Developments in the treatment of chronic hepatitis C.Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis.Natural killer and natural killer T cells in liver fibrosisBioconjugation of oligonucleotides for treating liver fibrosis.Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis.Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.In vivo inefficiency of pentoxifylline and interferon-alpha on hepatic fibrosis in biliary-obstructed rats: assessment by tissue collagen content and prolidase activity.Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.Renal histopathological lesions after orthotopic liver transplantation (OLT).Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B.
P2860
Q24201588-7AE2C3AB-E3AB-4996-8091-D3A721FBB531Q34022134-DC2145DE-C174-494E-8DE6-FCFDA2989289Q34189713-B25FD856-A56D-4ABC-913F-A3AC0F1AC56AQ34581499-1210C709-A532-436B-8797-92F4AE83668FQ35041900-2D0D14B4-D6A9-4A54-9E35-4E9365269D90Q35086844-8429BF73-A820-44A4-9D4C-E5CD7B380C6BQ35613902-620F1C95-DB98-4BF1-AFA1-41C974E0D407Q36553227-BF24D9D3-8301-4ED0-969C-FFA47165A034Q37043515-0F10BA3E-BF54-48EA-B1F5-C405E36BB25DQ37346066-AC65D8E8-768B-4564-8A05-54B5991EDBF4Q38689700-93E56E9C-B7F9-4E6A-8D5B-51EEE6A4E65FQ44373702-917A4731-4E09-429F-8399-58A6836B5BE3Q45145149-AF0A28BA-4366-43F0-88E8-4F4CE68980E6Q46427156-A9CE7BE1-6C4D-4A7B-91E1-EDAFA5517F8AQ50578674-0930043C-D504-4DDE-903F-AE983AF1A5E9Q50780787-67DE1195-5117-4A62-9DD1-391E632BCEDE
P2860
Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Long-term administration of in ...... f liver fibrosis over 5 years.
@en
Long-term administration of in ...... f liver fibrosis over 5 years.
@nl
type
label
Long-term administration of in ...... f liver fibrosis over 5 years.
@en
Long-term administration of in ...... f liver fibrosis over 5 years.
@nl
prefLabel
Long-term administration of in ...... f liver fibrosis over 5 years.
@en
Long-term administration of in ...... f liver fibrosis over 5 years.
@nl
P2093
P2860
P1476
Long-term administration of in ...... f liver fibrosis over 5 years.
@en
P2093
Chevallier M
Chossegros P
Desmoulière A
Grimaud JA
P2860
P304
P356
10.1046/J.1365-2893.1999.00148.X
P577
1999-03-01T00:00:00Z